 SOUTH SAN FRANCISCO, Calif., June 23, 2021 PRNewswire -- Titan Pharmaceuticals, Inc. NASDAQ: TTNP today announced that the in vivo study of its human kappa-opioid receptor agonist TP-2021, formerly JT-09 ProNeura-based implant in an established 5-guanidinonaltrindole 5-GNTI itch-induced mouse model, has demonstrated the potential to provide extended efficacy and durability in the treatment of moderate-to-severe chronic pruritus itch. 